UNSW Research Web and Researcher Profiles are undergoing scheduled maintenance between 9:00 am on 9th October 2024 and 5:00 pm on 9th October 2024.
Content changes made during this period will be lost. This maintenance does not impact InfoEd or other applications.

Select Publications

Preprints

Phetsouphanh C; Khoo WH; Jackson K; Klemm V; Howe A; Aggarwal A; Akerman A; Milogiannakis V; Stella AO; Rouet R; Schofield P; Faulks M; Law H; Danwilai T; Starr M; Munier ML; Christ D; Singh M; Croucher P; Brilot-Turville F; Turville S; Phan TG; Dore G; Darley D; Cunningham P; Matthews G; Kelleher A; Zaunders J, 2022, High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells, http://dx.doi.org/10.1101/2022.07.22.22277947

Aggarwal A; Stella A; Akerman A; Walker G; Milogiannakis V; McAllery S; Esneau C; Silva MR; Lu Y; Forster C; Hal SV; Mathivanan V; Fitcher C; Hoppe AC; Munier ML; Darley D; Matthews G; Starck D; Robosa R; Bartlett N; Rawlinson W; Kelleher A; Turville S, 2022, Rapid isolation and resolution immune evasion and viral fitness across contemporary SARS-CoV-2 variants, http://dx.doi.org/10.21203/rs.3.rs-1210846/v1

Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Kidinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Yeang M; Jean T; Foster C; Hoppe AC; Munier ML; Darley D; Churchill M; Starck D; Christ D; Matthews G; Rawlinson W; Kelleher A; Turville S, 2022, SARS-CoV-2 Omicron BA.5: Evolving Tropism and Evasion of Potent Humoral Responses and Resistance to Clinical Immunotherapeutics Relative to Viral Variants of Concern, http://dx.doi.org/10.2139/ssrn.4157473

Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Kidinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Coppola G; Yeang M; Jean T; Foster C; Hoppe AC; Ling Munier M; Darley D; Churchill M; Starck D; Christ D; Matthews G; Rawlinson W; Kelleher A; Turville S, 2022, SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, http://dx.doi.org/10.1101/2022.07.07.22277128

Gao X; Shen Q; Roco J; Frith K; Munier ML; Nekrasov M; Dalton B; He J-S; Jaeger R; Cook M; Zaunders J; Cockburn I, 2022, ZEB2 regulates the development of CD11c+ atypical B cells, http://dx.doi.org/10.1101/2022.09.01.506173

Aggarwal A; Stella AO; Walker G; Akerman A; Milogiannakis V; Brilot F; Amatayakul-Chantler S; Roth N; Coppola G; Schofield P; Jackson J; Henry J; Mazigi O; Langley D; Lu Y; Forster C; McAllery S; Mathivanan V; Fichter C; Hoppe AC; Munier ML; Jack H-M; Cromer D; Darley D; Matthews G; Christ D; Khoury D; Davenport M; Rawlinson W; Kelleher A; Turville S, 2021, SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, http://dx.doi.org/10.1101/2021.12.14.21267772


Back to profile page